NDUFAF2
ENSG00000164182
Target class
Enzyme
Chromosome
5
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFAF2
- Gene name
- NADH:ubiquinone oxidoreductase complex assembly factor 2
- Gene symbol
- NDUFAF2
- Previous gene symbols
- NDUFA12L
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 (B17.2-like) (B17.2L) (Mimitin) (Myc-induced mitochondrial protein) (MMTN) (NDUFA12-like protein)
- B17.2L
- MMTN
- mimitin
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial respiratory chain complex assembly factors
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 65.35
- Tissue specificity (Gini)
- 0.223
- Tissue specificity (tau)
- 0.602
- KEGG gene identifiers
- hsa:91942
- Reactome pathways
- R-HSA-6799198
- Protein interaction confidence
- 0.904644
- Protein interaction partners
- 59
- End position
- 61154531
- Start position
- 60945177
- Chromosome
- 5
- Strand
- Forward
- Mitochondrion .
- Mitochondria
Publication evidence
- PubMed 15774466
- Tissue specificity (tau)
- 0.601614
- Expression inequality (Gini)
- 0.223104
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 65.35
- Artery - Tibial
- 46.5
- Esophagus - Gastroesophageal Junction
- 43.42
- Artery - Aorta
- 41.31
- Esophagus - Muscularis
- 41.31
Expression in transcripts per million
- Cells - Cultured fibroblasts65.35
- Artery - Tibial46.5
- Esophagus - Gastroesophageal Junction43.42
- Artery - Aorta41.31
- Esophagus - Muscularis41.31
- Colon - Sigmoid39.93
- Artery - Coronary39.58
- Pituitary39.31
- Bladder37.11
- Ovary36.19
- Cervix - Endocervix36.18
- Cervix - Ectocervix35.97
- Cells - EBV-transformed lymphocytes34.84
- Testis34.58
- Nerve - Tibial34.26
- Uterus33.14
- Fallopian Tube32.65
- Adipose - Visceral (Omentum)31.9
- Adipose - Subcutaneous31.57
- Vagina30.71
- Breast - Mammary Tissue30.52
- Prostate28.33
- Muscle - Skeletal27.68
- Brain - Frontal Cortex (BA9)26.39
- Brain - Nucleus accumbens (basal ganglia)26.08
And 29 more, listed on the interactive page.
- GO:0032981
- GO:0060271
- GO:0005739
- GO:0005743
- GO:0005515
- GO:0044877
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor